Opinion|Podcasts|November 18, 2026

Pearls & Perspectives: Exploring Radiofrequency Therapy for Erectile Dysfunction, With Mohit Khera, MD

Fact checked by: Hannah Clarke

Mohit Khera, MD, MBA, MPH, discusses preliminary research on radiofrequency therapy as a potential treatment for vasculogenic erectile dysfunction.

In this episode of Pearls & Perspectives, recorded at the the 2026 Sexual Medicine Society of North America (SMSNA) Annual Meeting in Orlando, Florida, host Amy Pearlman, MD, sits down with Mohit Khera, MD, MBA, MPH, to discuss emerging research on radiofrequency therapy as a potential treatment for erectile dysfunction (ED), particularly in men with venous leak. Khera is a professor of urology at Baylor College of Medicine in Houston, Texas.

Khera explains how the growing interest in regenerative therapies for ED—including shockwave therapy, platelet-rich plasma (PRP), and stem cell therapy—has largely focused on improving penile blood flow. However, he notes that veno-occlusive dysfunction, in which men have difficulty maintaining an erection because of impaired blood outflow, represents an important treatment challenge. Radiofrequency offers a different approach by targeting the tunica albuginea, the collagen-rich tissue surrounding the erectile bodies, with the goal of remodeling and tightening the tissue to reduce venous leakage.

Khera reviews preliminary findings from a study of 15 patients who received weekly radiofrequency treatments over 6 weeks.1 The approach uses controlled heating to promote collagen remodeling without damaging surrounding tissue. Overall, 93.3% of patients demonstrated improvement in IIEF-6 scores from baseline, and 73.3% achieved the minimum clinically important difference, defined as 4 points or greater. No adverse events were recorded.

Although patients experienced significant improvements in erectile function, Khera emphasizes that the findings are preliminary and not yet sufficient to change clinical practice. He discusses plans for a national, randomized, placebo-controlled trial to further evaluate the technology. The conversation also addresses treatment considerations, including the device's temperature-controlled safety mechanism, the management of patients already taking phosphodiesterase type 5 inhibitors during the study, and the potential role of combining radiofrequency with other regenerative approaches.

Pearlman and Khera also explore the broader implications of developing treatments that address the underlying mechanisms of ED rather than simply helping men achieve an erection. Khera discusses the limitations of current approaches to venous leak, which primarily involve erection rings or attempts to increase arterial inflow through medication or injections. He also considers the potential for combining therapies that target different contributors to ED, such as radiofrequency for venous occlusive dysfunction and shockwave therapy for arterial insufficiency. The discussion highlights the potential value of innovation in sexual medicine while underscoring the need for more rigorous clinical evidence before these emerging treatments can be incorporated into practice.

REFERENCE

1. Walia A, Hernandez B, Coady P, Oppenheimer A, Kohn T. Khera M. Radiofrequency Therapy for Vasculogenic Erectile Dysfunction: A Prospective Pilot Cohort Study. Presented at: 27th Annual Fall Scientific Meeting of SMSNA. October 8-11, 2026. Orlando, Florida. Abstract 159


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.